Glioma proteomics: status and perspectives.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Proteomics

• Publication date

  2010-09-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jprot.2010.03.007PMID 20332038
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme.

  2010cited by this paper
• Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatography- and mass spectrometry-based approaches.

  2009cited by this paper
• iTRAQ-based Proteomics Profiling Reveals Increased Metabolic Activity and Cellular Cross-talk in Angiogenic Compared with Invasive Glioblastoma Phenotype*

  2009cited by this paper
• Differential genomic and proteomic profiling of glioblastoma cells exposed to terpyridineplatinum(II) complexes.

  2009cited by this paper
• Serum proteomics of glioma: methods and applications

  2009cited by this paper
• Multidimensional protein identification technology for clinical proteomic analysis

  2009cited by this paper
• Multifarious proteomic signatures and regional heterogeneity in glioblastomas

  2009cited by this paper
• Proteomics by mass spectrometry: approaches, advances, and applications.

  2009cited by this paper
• Clinical Applications of Metabolomics in Oncology: A Review

  2009cited by this paper
• IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas

  2009cited by this paper
• Proteomics strategies for target identification and biomarker discovery in cancer.

  2009cited by this paper
• Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme

  2009cited by this paper
• Targeted proteomic strategy for clinical biomarker discovery

  2009cited by this paper
• Identification of gliotropic factors that induce human stem cell migration to malignant tumor.

  2009cited by this paper
• MALDI Imaging Mass Spectrometry

  2009cited by this paper
• Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.

  2009cited by this paper
• Glioblastoma Multiforme Oncogenomics and Signaling Pathways

  2009cited by this paper
• Cancer stem cells and angiogenesis.

  2009cited by this paper
• Identification of secreted proteins regulated by cAMP in glioblastoma cells using glycopeptide capture and label‐free quantification

  2009cited by this paper
• Mass spectrometry for proteomics.

  2008cited by this paper
• Applications of mass spectrometry in metabolomic studies of animal model and invertebrate systems.

  2008cited by this paper
• Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy

  2008cited by this paper
• Up-regulation of NG2 proteoglycan and interferon-induced transmembrane proteins 1 and 3 in mouse astrocytoma: a membrane proteomics approach.

  2008cited by this paper
• SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function.

  2008cited by this paper
• Unique proteomic features induced by a potential antiglioma agent, Nordy (dl‐nordihydroguaiaretic acid), in glioma cells

  2008cited by this paper
• Integrated analysis of the cerebrospinal fluid peptidome and proteome.

  2008cited by this paper
• Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma.

  2008cited by this paper
• Reverse-phase protein lysate microarrays for cell signaling analysis

  2008cited by this paper
• Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers

  2008cited by this paper
• Expression Sites of Colligin 2 in Glioma Blood Vessels

  2008cited by this paper
• Identification of a novel proliferation-related protein, WHSC1 4a, in human gliomas.

  2008cited by this paper
• Epitope mapping of antibodies using bacterial surface display

  2008cited by this paper
• Selected reaction monitoring for quantitative proteomics: a tutorial

  2008cited by this paper
• Glucose metabolites, glutamate and glycerol in malignant glioma tumours during radiotherapy

  2008cited by this paper
• The epitope space of the human proteome

  2008cited by this paper
• A metabolomics perspective of human brain tumours

  2007cited by this paper
• Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer

  2007cited by this paper
• Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression.

  2007cited by this paper
• Discovery of serum biomarkers in astrocytoma by SELDI–TOF MS and proteinchip technology

  2007cited by this paper
• Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

  2007cited by this paper
• Identification of Glioma Neovascularization-related Proteins by Using MALDI-FTMS and Nano-LC Fractionation to Microdissected Tumor Vessels*

  2007cited by this paper
• Clinical proteomics: A need to define the field and to begin to set adequate standards

  2007cited by this paper
• The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas.

  2007cited by this paper
• Biomarker discovery: A proteomic approach for brain cancer profiling

  2007cited by this paper
• Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients.

  2007cited by this paper
• Protein disulfide isomerase expression is related to the invasive properties of malignant glioma.

  2006cited by this paper
• Proteome profile changes that are differentially regulated by lipid and protein phosphatase activities of tumor suppressor PTEN in PTEN‐expressing U‐87 MG human glioblastoma cells

  2006cited by this paper
• Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays

  2006cited by this paper
• Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF.

  2006cited by this paper
• CNS Tumors: Monitoring Therapeutic Response and Outcome Prediction

  2006cited by this paper
• Analysis of Glioma Cell Platinum Response by Metacomparison of Two-dimensional Chromatographic Proteome Profiles*

  2006cited by this paper
• Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers

  2006cited by this paper
• Proteomic profiling distinguishes astrocytomas and identifies differential tumor markers

  2006cited by this paper
• Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment

  2006cited by this paper
• Detecting differential and correlated protein expression in label-free shotgun proteomics.

  2006cited by this paper
• Attractin Is Elevated in the Cerebrospinal Fluid of Patients with Malignant Astrocytoma and Mediates Glioma Cell Migration

  2006cited by this paper
• Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions

  2006cited by this paper
• Proteomics-based analysis of a pair of glioma cell lines with different tumor forming characteristics.

  2006cited by this paper
• Comparison of Label-free Methods for Quantifying Human Proteins by Shotgun Proteomics*S

  2005cited by this paper
• Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry.

  2005cited by this paper
• Proteome-based identification of molecular markers predicting chemosensitivity to each category of anticancer agents in human gliomas.

  2005cited by this paper
• Proteins and Protein Pattern Differences between Glioma Cell Lines and Glioblastoma Multiforme

  2005cited by this paper
• Proteome analysis of microdissected tumor tissue using a capillary isoelectric focusing-based multidimensional separation platform coupled with ESI-tandem MS.

  2005cited by this paper
• Proteomic studies on low- and high-grade human brain astrocytomas.

  2005cited by this paper
• Differential protein expression in human gliomas and molecular insights

  2005cited by this paper
• High-throughput identification of in-gel digested proteins by rapid, isocratic HPLC/MS/MS.

  2005cited by this paper
• Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.

  2005cited by this paper
• Imaging Mass Spectrometry: Principles and Potentials

  2005cited by this paper
• Molecular Classification and Survival Prediction in Human Gliomas Based on Proteome Analysis

  2004cited by this paper
• Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme.

  2004cited by this paper
• Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents*S

  2004cited by this paper
• Protein patterns and proteins that identify subtypes of glioblastoma multiforme

  2004cited by this paper
• Protein Profiling in Brain Tumors Using Mass Spectrometry

  2004cited by this paper
• Intraobserver reproducibility in assigning brain tumors to classes in the world health organization diagnostic scheme

  2004cited by this paper
• Mass spectrometry-based proteomics

  2003cited by this paper
• The Human Plasma Proteome

  2002cited by this paper
• Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics*

  2002cited by this paper
• Quantitative proteomic analysis using a MALDI quadrupole time-of-flight mass spectrometer.

  2001cited by this paper
• Gliomagenesis: genetic alterations and mouse models

  2001cited by this paper
• World Health Organization classification of tumors

  2000cited by this paper
• Discrepancies in diagnoses of neuroepithelial neoplasms

  2000cited by this paper
• Direct analysis of protein complexes using mass spectrometry

  1999cited by this paper
• Quantitative analysis of complex protein mixtures using isotope-coded affinity tags

  1999cited by this paper
• Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

  1998cited by this paper
• Diagnostic discrepancies and their clinical impact in a neuropathology referral practice

  1997cited by this paper
• Protein sequencing by tandem mass spectrometry.

  1986cited by this paper

• Research Progress on the Application of Radiomics in the Diagnosis and Treatment of Gliomas

  2025cites this paper
• Application of the Mass Spectrometry–High‐Throughput Technique Over the Immunohistochemical Analysis for Human Brain Tumor Diagnosis and Prognosis: Insights Into Biomarkers' Identification for the Case Study of Grade IV Astrocytomas and Meningiomas

  2025cites this paper
• Evaluation the Age and Gender Association in Iraqi Patients with High Grade Glioma

  2025cites this paper
• Identification of Population-Specific Novel Protein Biomarkers and Possible Therapeutic Targets in Gliomas by Proteomics Approach

  2024cites this paper
• Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics

  2023cites this paper
• An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?

  2023cites this paper
• Differential Proteome Profiling Analysis under Pesticide Stress by the Use of a Nano-UHPLC-MS/MS Untargeted Proteomic-Based Approach on a 3D-Developed Neurospheroid Model: Identification of Protein Interactions, Prognostic Biomarkers, and Potential Therapeutic Targets in Human IDH Mutant High-Grade

  2023cites this paper
• Quantitative proteomic analysis of GnRH agonist treated GBM cell line LN229 revealed regulatory proteins inhibiting cancer cell proliferation

  2022cites this paper
• Moschamindole induces glioma cell apoptosis by blocking Mia40‐dependent mitochondrial intermembrane space assembly and oxidative respiration

  2021cites this paper
• The Big Picture of Glioblastoma Malignancy: A Meta-Analysis of Glioblastoma Proteomics to Identify Altered Biological Pathways

  2021cites this paper
• The miR-142 Suppresses U-87 Glioblastoma Cell Growth by Targeting EGFR Oncogenic Signaling Pathway

  2021cites this paper
• Plasma-Derived Extracellular Vesicles Reveal Galectin-3 Binding Protein as Potential Biomarker for Early Detection of Glioma

  2021cites this paper
• Circulating Biomarkers for Glioma: A Review.

  2021cites this paper
• Novel management of glioma by molecular therapies, a review article

  2019cites this paper
• Review on Immunological Biomarkers in Gliomas

  2019cites this paper
• SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways

  2019cites this paper
• Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches

  2019cites this paper
• microRNA-4500 inhibits human glioma cell progression by targeting IGF2BP1.

  2019cites this paper
• Prospects of translational proteomics and protein microarrays in oligodendroglioma

  2019cites this paper
• 7 Glioma Proteomics : Methods and Current Perspective

  2018cites this paper
• Adipocyte proteome and secretome influence inflammatory and hormone pathways in glioma

  2018cites this paper
• Exploring Long Noncoding RNAs in Glioblastoma: Regulatory Mechanisms and Clinical Potentials

  2018cites this paper
• Enhanced proteasomal activity is essential for long term survival and recurrence of innately radiation resistant residual glioblastoma cells

  2018cites this paper
• Multi‐pronged proteomic analysis to study the glioma pathobiology using cerebrospinal fluid samples

  2018cites this paper
• Identification of Plasma Membrane Glycoproteins Specific to Human Glioblastoma Multiforme Cells Using Lectin Arrays and LC‐MS/MS

  2018cites this paper
• Recherche de biomarqueurs protéiques dans le but de réaliser une classification moléculaire des gliomes : étude GLIOMIC

  2017cites this paper
• Snail homolog 1 is involved in epithelial-mesenchymal transition-like processes in human glioblastoma cells.

  2017cites this paper
• Quantitative validation of anti‐PTBP1 antibody for diagnostic neuropathology use: Image analysis approach

  2017cites this paper
• Evaluation of non-supervised MALDI mass spectrometry imaging combined with microproteomics for glioma grade III classification.

  2017cites this paper
• Insights into molecular therapy of glioma: current challenges and next generation blueprint

  2017cites this paper
• Targeting Malignant Brain Tumors with Antibodies

  2017cites this paper
• ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models

  2016cites this paper
• De la classification moléculaire des gliomes à une nouvelle stratégie thérapeutique de réactivation des macrophages au sein de la tumeur

  2016cites this paper
• Evaluation of 188Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model

  2015cites this paper
• Identification of Circulating MicroRNAs as Biomarkers in Glioblastoma

  2015cites this paper
• RNA interference targeting hypoxia-inducible factor 1α via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model.

  2015cites this paper
• A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model

  2015cites this paper
• Advances in Omics Technologies in GBM

  2015cites this paper
• A Unique Four-Hub Protein Cluster Associates to Glioblastoma Progression

  2014cites this paper
• Identification of Novel Tumor-Associated Cell Surface Sialoglycoproteins in Human Glioblastoma Tumors Using Quantitative Proteomics

  2014cites this paper
• Towards developing biomarkers for glioblastoma multiforme: a proteomics view

  2014cites this paper
• Lipidomic analysis of glioblastoma multiforme

  2014cites this paper
• Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics.

  2014cites this paper
• Proteomic Approaches in Biomarker Discovery: New Perspectives in Cancer Diagnostics

  2014cites this paper
• Proteomic analysis underlines the usefulness of both primary adherent and stem-like cell lines for studying proteins involved in human glioblastoma.

  2014cites this paper
• Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas

  2014influential citation
• Senescence-associated-gene signature identifies genes linked to age, prognosis, and progression of human gliomas.

  2014cites this paper
• Proteomic analysis of hypoxia‐induced U373MG glioma secretome reveals novel hypoxia‐dependent migration factors

  2014cites this paper
• Prioritizing uncharacterized genes in the search for glioma biomarkers.

  2014cites this paper
• Association study of a functional copy number variation in the WWOX gene with risk of gliomas among Chinese people

  2014cites this paper
• Lipidomic Analysis of Glioblastoma Multiforme Using Mass Spectrometry

  2014cites this paper
• Costa Proteomic Analysis of the Influence of the Adipocyte Secretome on Glioma Gl 261 Cells

  2014cites this paper
• Role of Amide Proton Transfer (APT)-MRI of Endogenous Proteins and Peptides in Brain Tumor Imaging

  2014cites this paper
• Circulating MicroRNA Biomarkers for Glioma and Predicting Response to Therapy

  2014cites this paper
• Experimentalvalidationof5in-silicopredicted glioma biomarkers

  2013cites this paper
• Advances in the proteomic discovery of novel therapeutic targets in cancer

  2013cites this paper
• Combined Effect of Tissue Stabilization and Protein Extraction Methods on Phosphoprotein Analysis

  2013cites this paper
• Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines.

  2013cites this paper
• Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.

  2013cites this paper
• ELTD1, a potential new biomarker for gliomas.

  2013cites this paper
• Subtyping of gliomas of various WHO grades by the application of immunohistochemistry

  2013cites this paper
• Proteomic analysis of glioblastomas: what is the best brain control sample?

  2013cites this paper
• Experimental validation of 5 in-silico predicted glioma biomarkers.

  2013cites this paper
• Mitochondrial dysfunction in gliomas.

  2013cites this paper
• Proteomic Studies in Low-Grade Gliomas: What Have They Informed About Pathophysiology?

  2013cites this paper
• Proteomic Analysis of the Influence of the Adipocyte Secretome on Glioma Gl261 Cells

  2013cites this paper
• Proteomic analysis reveals drug accessible cell surface N-glycoproteins of primary and established glioblastoma cell lines.

  2012cites this paper
• LC-MS/MS Analysis of Differentially Expressed Glioblastoma Membrane Proteome Reveals Altered Calcium Signaling and Other Protein Groups of Regulatory Functions*

  2012cites this paper
• Title Protein alterations associated with temozolomide resistance insubclones of human glioblastoma cell lines

  2012cites this paper
• Proteomic Analysis of Glioma Chemoresistance

  2012cites this paper
• Investigation of serum proteome alterations in human glioblastoma multiforme

  2012cites this paper
• Quantitative proteomic Isotope-Coded Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma.

  2012cites this paper
• Glioblastoma cell secretome: analysis of three glioblastoma cell lines reveal 148 non-redundant proteins.

  2011cites this paper
• Assessment of Rodent Glioma Models Using Magnetic Resonance Imaging Techniques

  2011influential citation
• Proteomic data in meningiomas: post-proteomic analysis can reveal novel pathophysiological pathways

  2011cites this paper
• Saturation power dependence of amide proton transfer image contrasts in human brain tumors and strokes at 3 T

  2011cites this paper
• Glioma Proteomics: Methods and Current Perspective

  2011cites this paper
• Proteomics of gliomas: initial biomarker discovery and evolution of technology.

  2011cites this paper
• Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach

  2011cites this paper
• Integration and analysis of genome-scale data from gliomas

  2011cites this paper
• Method for lipidomic analysis: p53 expression modulation of sulfatide, ganglioside, and phospholipid composition of U87 MG glioblastoma cells.

  2007cites this paper